Large-scale testing (Phase 3)Study completedNCT03511664What this trial is testingStudy of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate CancerWho this might be right forProstate Cancer Endocyte 861
Testing effectiveness (Phase 2)Study completedNCT03888612What this trial is testingTrial of ARV-110 in Patients With Metastatic Castration Resistant Prostate CancerWho this might be right forProstate Cancer Metastatic Arvinas Inc. 248
Testing effectiveness (Phase 2)Looking for participantsNCT07002320What this trial is testingInvestigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate CancerWho this might be right forMetastatic Castrate-Resistant Prostate Cancer (mCRPC) Institute of Cancer Research, United Kingdom 78
Large-scale testing (Phase 3)Ended earlyNCT02057666What this trial is testingStudy Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate CancerWho this might be right forProstatic Neoplasms, Castration-Resistant Ipsen 146
Early research (Phase 1)Ended earlyNCT02963051What this trial is testingA Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate CancerWho this might be right forProstate Cancer Daniel George, MD 9
Testing effectiveness (Phase 2)Ended earlyNCT03770455What this trial is testingAvelumab Plus 2nd-generation ADT in African American Subjects With mCRPCWho this might be right forMetastatic Castration-resistant Prostate Cancer Jodi Layton, MD 8
Testing effectiveness (Phase 2)Looking for participantsNCT07441889What this trial is testingHER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)Who this might be right forBreast CancerProstate Cancer University of Virginia 23
Early research (Phase 1)Study completedNCT02826772What this trial is testingSafety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate CancerWho this might be right forMetastatic Castrate Resistant Prostate Cancer (mCRPC) Suzhou Kintor Pharmaceutical Inc, 40
Testing effectiveness (Phase 2)Looking for participantsNCT06134232What this trial is testingMetastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-TWho this might be right forMetastatic Castration-Resistant Prostate Cancer (mCRPC) Dendreon 400
Not applicableStudy completedNCT02899104What this trial is testingNavigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )Who this might be right forProstatic Neoplasms, Castration-Resistant Bayer 200
Testing effectiveness (Phase 2)Study completedNCT01487863What this trial is testingConcurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate CancerWho this might be right forProstate Cancer MetastaticHormone Refractory Prostate CancerCastration-resistant Prostate Cancer Dendreon 69
Testing effectiveness (Phase 2)Active Not RecruitingNCT05658003What this trial is testingA Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate CancerWho this might be right forMetastatic Castration-Resistant Prostate Cancer (mCRPC) Novartis Pharmaceuticals 63
Testing effectiveness (Phase 2)Study completedNCT05655715What this trial is testingCheckpoint Inhibitors and SBRT for MCRPCWho this might be right forProstate Cancer MetastaticCastrate Resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer+1 more Herlev and Gentofte Hospital 90
Testing effectiveness (Phase 2)WithdrawnNCT05191017What this trial is testingStudy of NUV-422 in Combination With Enzalutamide in Patients With mCRPCWho this might be right forProstate CancerProstatic CancerCancer of Prostate+5 more Nuvation Bio Inc.
Early research (Phase 1)Study completedNCT01823978What this trial is testingSafety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate CancerWho this might be right forCastrate Resistent Prostate Cancer Bellicum Pharmaceuticals 19
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07592910What this trial is testingMevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor TherapyWho this might be right forMetastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (Adenocarcinoma) Prostate Cancer Clinical Trials Consortium 60
Testing effectiveness (Phase 2)Study completedNCT00942578What this trial is testingTrial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate CancerWho this might be right forMetastatic Prostate Cancer National Cancer Institute (NCI) 63
Large-scale testing (Phase 3)Active Not RecruitingNCT04647526What this trial is testingStudy Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentWho this might be right forMetastatic Castration-Resistant Prostate Cancer POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company 455
Testing effectiveness (Phase 2)UnknownNCT02266745What this trial is testingA Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion CohortsWho this might be right forAdvanced Solid TumorsCRPCmCRPC+6 more Promontory Therapeutics Inc. 109
Large-scale testing (Phase 3)UnknownNCT05627752What this trial is testingDocetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC StageWho this might be right forProstate CancerCastrate Resistant Prostate Cancer Zhongnan Hospital 120